title: Preclinical evaluation of a mercaptobenzamide and its prodrug for NCp7-targeted inhibition of human immunodeficiency virus.
abstract: Although the effective use of highly active antiretroviral therapy results in the suppression of virus production in infected individuals, it does not eliminate the infection and low level virus production in cells harboring virus in sanctuary sites. Thus, the continued search for new antiretroviral agents with unique and different mechanisms of HIV inhibition remains critical, and compounds that can reduce the level of virus production from cells already infected with HIV, as opposed to preventing de novo infection, would be of great benefit. A mercaptobenzamide (MDH-1-38) and its prodrug (NS1040) are being developed as potential therapeutic compounds targeting the zinc finger of HIV nucleocapsid. In the presence of esterase enzymes, NS1040 is designed to be converted to MDH-1-38 which has antiviral activity. While we presume that NS1040 is rapidly converted to MDH-1-38 in all experiments, the two compounds were tested side-by-side to determine whether the presence of a prodrug affects the antiviral activity or mechanism of action. The two compounds were evaluated against a panel of HIV-1 clinical isolates in human PBMCs and monocyte-macrophages and yielded EC50values ranging from 0.7 to 13 μM with no toxicity up to 100 μM. MDH-1-38 and NS1040 remained equally active in human PBMCs in the presence of added serum proteins as well as against HIV-1 isolates resistant to reverse transcriptase, integrase or protease inhibitors. Cell-based and biochemical mechanism of antiviral action assays demonstrated MDH-1-38 and NS1040 were virucidal at concentrations of 15 and 50 μM, respectively. Cell to cell transmission of HIV in multiple passages was significantly reduced in CEM-SS and human PBMCs by reducing progeny virus infectivity at compound concentrations greater than 2 μM. The combination of either MDH-1-38 or NS1040 with other FDA-approved HIV drugs yielded additive to synergistic antiviral interactions with no evidence of antiviral antagonism or synergistic toxicity. Serial dose escalation was used in attempts to select for HIV strains resistant to MDH-1-38 and NS1040. Virus at several passages failed to replicate in cells treated at increased compound concentrations, which is consistent with the proposed mechanism of action of the virus inactivating compounds. Through 14 passages, resistance to the compounds has not been achieved. Most HIV inhibitors with mechanism of antiviral action targeting a viral protein would have selected for a drug resistant virus within 14 passages. These studies indicate that these NCp7-targeted compounds represent new potent anti-HIV drug candidates which could be effectively used in combination with all approved anti-HIV drugs.
authors: ImQuest Biosciences, Frederick, MD, USA.
authors: T L
authors: TL
authors: Hartman
authors: ImQuest Biosciences, Frederick, MD, USA.
authors: L
authors: L
authors: Yang
authors: ImQuest Biosciences, Frederick, MD, USA.
authors: A N
authors: AN
authors: Helfrick
authors: Laboratory of Bioorganic Chemistry, NIDDK, NIH, Bethesda, MD, USA.
authors: M
authors: M
authors: Hassink
authors: Laboratory of Bioorganic Chemistry, NIDDK, NIH, Bethesda, MD, USA.
authors: N I
authors: NI
authors: Shank
authors: Laboratory of Bioorganic Chemistry, NIDDK, NIH, Bethesda, MD, USA.
authors: K
authors: K
authors: George Rosenker
authors: Laboratory of Bioorganic Chemistry, NIDDK, NIH, Bethesda, MD, USA.
authors: M T
authors: MT
authors: Scerba
authors: Laboratory of Bioorganic Chemistry, NIDDK, NIH, Bethesda, MD, USA.
authors: M
authors: M
authors: Saha
authors: NCATS, NIH, Bethesda, MD, USA.
authors: E
authors: E
authors: Hughes
authors: NCATS, NIH, Bethesda, MD, USA.
authors: A Q
authors: AQ
authors: Wang
authors: NCATS, NIH, Bethesda, MD, USA.
authors: X
authors: X
authors: Xu
authors: Laboratory of Bioorganic Chemistry, NIDDK, NIH, Bethesda, MD, USA.
authors: P
authors: P
authors: Gupta
authors: ImQuest Biosciences, Frederick, MD, USA. Electronic address: rbuckheit@imquestbio.com.
authors: R W
authors: RW
authors: Buckheit
authors: Laboratory of Bioorganic Chemistry, NIDDK, NIH, Bethesda, MD, USA. Electronic address: appellad@niddk.nih.gov.
authors: D H
authors: DH
authors: Appella
mesh_terms: D019380:Anti-HIV Agents / Q000737:chemistry / Q000494:pharmacology*; D001562:Benzimidazoles / Q000737:chemistry / Q000494:pharmacology*; D055808:Drug Discovery; D004353:Drug Evaluation, Preclinical; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000821:virology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008264:Macrophages / Q000821:virology; D009000:Monocytes / Q000821:virology; D011355:Prodrugs / Q000494:pharmacology*; D014779:Virus Replication / Q000187:drug effects; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000187:drug effects*
chemical_list: D019380:Anti-HIV Agents; D001562:Benzimidazoles; C071884:NCP7 protein, Human immunodeficiency virus 1; D011355:Prodrugs; D054301:gag Gene Products, Human Immunodeficiency Virus